Filing Details

Accession Number:
0000919574-25-002726
Form Type:
13G Filing
Publication Date:
2025-05-01 20:00:00
Filed By:
ABG WTT-Ceribell Limited
Company:
Ceribell Inc.
Filing Date:
2025-05-02
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Beneficially Owned Number of Shares Beneficially Owned Number of Aggregate Shares Percent of Class
ABG WTT-Ceribell Limited 0 2,441,267 6.8%
ABG V-Ceribell Limited 0 2,441,267 6.8%
Ally Bridge Group Global Life Science Capital Partners V, L.P. 0 2,441,267 6.8%
ABG Global Life Science Capital Partners V GP, L.P. 0 2,441,267 6.8%
ABG Global Life Science Capital Partners V GP Limited 0 2,441,267 6.8%
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. 0 2,441,267 6.8%
ABG-WTT Global Life Science Capital Partners GP, L.P. 0 2,441,267 6.8%
ABG-WTT Global Life Science Capital Partners GP Limited 0 2,441,267 6.8%
ABG Management Ltd. 0 2,441,267 6.8%
Ally Bridge Group (PE) LLC 0 2,441,267 6.8%
Fan Yu 0 2,441,267 6.8%
Filing





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox checked   Rule 13d-1(d)






SCHEDULE 13G



Comment for Type of Reporting Person:  The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.


SCHEDULE 13G



Comment for Type of Reporting Person:  ABG V-Ceribell Limited is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.


SCHEDULE 13G



Comment for Type of Reporting Person:  Ally Bridge Group Global Life Science Capital Partners V, L.P. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.


SCHEDULE 13G



Comment for Type of Reporting Person:  ABG Global Life Science Capital Partners V GP, L.P. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.


SCHEDULE 13G



Comment for Type of Reporting Person:  ABG Global Life Science Capital Partners V GP Limited is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.


SCHEDULE 13G



Comment for Type of Reporting Person:  Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.


SCHEDULE 13G



Comment for Type of Reporting Person:  ABG-WTT Global Life Science Capital Partners GP, L.P. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.


SCHEDULE 13G



Comment for Type of Reporting Person:  ABG-WTT Global Life Science Capital Partners GP Limited is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.


SCHEDULE 13G



Comment for Type of Reporting Person:  ABG Management Ltd. is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.


SCHEDULE 13G



Comment for Type of Reporting Person:  Ally Bridge Group (PE) LLC is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.


SCHEDULE 13G



Comment for Type of Reporting Person:  Fan Yu is in a position to, directly or indirectly, exercise or share the ultimate voting and disposition control of the Common Stock owned by ABG WTT-Ceribell Limited. The percentage of ownership based on 35,868,339 shares of Common Stock of the Issuer outstanding as of February 21, 2025, as reported on the Issuer's Form 10-K filed on February 25, 2025.


SCHEDULE 13G


 
ABG WTT-Ceribell Limited
 
Signature:/s/ Kevin Reilly
Name/Title:Kevin Reilly, Director
Date:05/02/2025
 
ABG V-Ceribell Limited
 
Signature:/s/ Kevin Reilly
Name/Title:Kevin Reilly, Director
Date:05/02/2025
 
Ally Bridge Group Global Life Science Capital Partners V, L.P.
 
Signature:By: ABG Global Life Science Capital Partners V GP, L.P., its general partner, By: ABG Global Life Science Capital Partners V GP Limited, its general p
Name/Title:Fan Yu, Director
Date:05/02/2025
 
ABG Global Life Science Capital Partners V GP, L.P.
 
Signature:By: ABG Global Life Science Capital Partners V GP Limited, its general partner, By: /s/ Fan Yu
Name/Title:Fan Yu, Director
Date:05/02/2025
 
ABG Global Life Science Capital Partners V GP Limited
 
Signature:/s/ Fan Yu
Name/Title:Fan Yu, Director
Date:05/02/2025
 
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.
 
Signature:By: ABG-WTT Global Life Science Capital Partners GP, L.P., its general partner, By: ABG-WTT Global Life Science Capital Partners GP Limited, its gener
Name/Title:Fan Yu, Director
Date:05/02/2025
 
ABG-WTT Global Life Science Capital Partners GP, L.P.
 
Signature:By: ABG-WTT Global Life Science Capital Partners GP Limited, its general partner, By: /s/ Fan Yu
Name/Title:Fan Yu, Director
Date:05/02/2025
 
ABG-WTT Global Life Science Capital Partners GP Limited
 
Signature:/s/ Fan Yu
Name/Title:Fan Yu, Director
Date:05/02/2025
 
ABG Management Ltd.
 
Signature:/s/ Fan Yu
Name/Title:Fan Yu, Director
Date:05/02/2025
 
Ally Bridge Group (PE) LLC
 
Signature:By: ABG Management Ltd., its managing member, By: /s/ Fan Yu
Name/Title:Fan Yu, Director
Date:05/02/2025
 
Fan Yu
 
Signature:/s/ Fan Yu
Name/Title:Fan Yu
Date:05/02/2025
Exhibit Information

[Exhibit A - Joint Filing Agreement]